Agios Pharmaceuticals, Inc.
AGIO
$28.42
$0.431.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M |
| Cost of Revenue | 82.47M | 89.94M | 88.48M | 93.64M | 73.83M |
| Gross Profit | -61.72M | -69.97M | -75.60M | -81.19M | -65.10M |
| SG&A Expenses | 48.30M | 51.61M | 41.27M | 45.87M | 41.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 130.77M | 141.55M | 129.75M | 139.51M | 115.36M |
| Operating Income | -110.03M | -121.58M | -116.87M | -127.06M | -106.63M |
| Income Before Tax | -99.11M | -109.06M | -103.43M | -112.02M | -89.29M |
| Income Tax Expenses | -- | -1.02M | -- | -- | -- |
| Earnings from Continuing Operations | -99.11M | -108.04M | -103.43M | -112.02M | -89.29M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -99.11M | -108.04M | -103.43M | -112.02M | -89.29M |
| EBIT | -110.03M | -121.58M | -116.87M | -127.06M | -106.63M |
| EBITDA | -108.66M | -120.31M | -115.50M | -125.80M | -105.35M |
| EPS Basic | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 |
| Normalized Basic EPS | -1.05 | -1.17 | -1.11 | -1.21 | -0.97 |
| EPS Diluted | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 |
| Normalized Diluted EPS | -1.05 | -1.17 | -1.11 | -1.21 | -0.97 |
| Average Basic Shares Outstanding | 58.78M | 58.35M | 58.14M | 57.93M | 57.46M |
| Average Diluted Shares Outstanding | 58.78M | 58.35M | 58.14M | 57.93M | 57.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |